Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346977 | 0.90 | EPHX2 (0.41) | KMT2AMAPTEPHX2MEN1ACKR3 | |
| SCHEMBL346910 | 0.88 | ALDH1A1 (0.41) | EPHX2ACKR3 | |
| SCHEMBL347603 | 0.87 | EPHX2 (0.39) | MAPTEPHX2ACKR3SMN1; SMN2 | |
| SCHEMBL348333 | 0.86 | TP53 (0.41) | KMT2ATP53MAPTEPHX2MEN1 | |
| SCHEMBL1020415 | 0.85 | HTT (0.46) | KMT2ATP53MAPTMEN1ACKR3 | |
| SCHEMBL1019694 | 0.82 | HTT (0.44) | KMT2ATP53MAPTMEN1ACKR3 | |
| SCHEMBL347867 | 0.82 | TP53 (0.43) | KMT2ATP53MAPTEPHX2MEN1 | |
| SCHEMBL19128856 | 0.80 | EPHX2 (0.40) | MAPTEPHX2ACKR3 | |
| SCHEMBL1019054 | 0.79 | HTT (0.44) | KMT2ATP53MAPTEPHX2MEN1 | |
| SCHEMBL1020948 | 0.79 | HTT (0.44) | KMT2ATP53MAPTEPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | claimed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | claimed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | claimed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2018222975-A1 | METHODS FOR THE TREATMENT OF CANCER | RGENIX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-3402477-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | The Rockefeller University (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017123568-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2016100619-A2 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | KMT2A 729/4885TP53 1276/4885MAPT 3623/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | KMT2A 729/4885TP53 1276/4885MAPT 3623/4885 |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | KMT2A 729/4885TP53 1276/4885MAPT 3623/4885 |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | NR1H4, NR1H3, NR1H2 | KMT2A 1900/4885TP53 540/4885MAPT 4774/4885 |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | KMT2A 4136/4885TP53 4394/4885MAPT 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.